Alimera Sciences (NASDAQ:ALIM) Stock Rating Reaffirmed by HC Wainwright

Alimera Sciences (NASDAQ:ALIM - Get Free Report)'s stock had its "buy" rating reissued by HC Wainwright in a research note issued to investors on Thursday, Benzinga reports. They presently have a $6.00 price target on the biopharmaceutical company's stock. HC Wainwright's price target would suggest a potential upside of 82.93% from the company's previous close.

Other analysts also recently issued reports about the company. StockNews.com downgraded Alimera Sciences from a "buy" rating to a "hold" rating in a research note on Tuesday, April 30th. Maxim Group assumed coverage on Alimera Sciences in a research report on Monday, March 25th. They issued a "buy" rating and a $10.00 target price on the stock.

Alimera Sciences Price Performance

Shares of Alimera Sciences stock traded up $0.01 during trading hours on Thursday, reaching $3.28. 62,448 shares of the company's stock were exchanged, compared to its average volume of 72,748. The business has a fifty day moving average of $3.72 and a two-hundred day moving average of $3.68. The company has a market capitalization of $171.79 million, a P/E ratio of -2.08 and a beta of 1.20. The company has a quick ratio of 2.31, a current ratio of 2.39 and a debt-to-equity ratio of 1.40. Alimera Sciences has a 1 year low of $1.86 and a 1 year high of $4.38.

Alimera Sciences (NASDAQ:ALIM - Get Free Report) last announced its quarterly earnings data on Tuesday, May 14th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.08). The business had revenue of $23.01 million for the quarter, compared to analysts' expectations of $23.72 million. Alimera Sciences had a negative net margin of 24.93% and a negative return on equity of 130.90%. During the same period in the prior year, the company posted ($0.71) EPS. As a group, research analysts predict that Alimera Sciences will post 0.03 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alimera Sciences

A number of hedge funds have recently made changes to their positions in the stock. AIGH Capital Management LLC purchased a new position in shares of Alimera Sciences during the third quarter worth $7,355,000. Stonepine Capital Management LLC purchased a new stake in shares of Alimera Sciences during the third quarter worth approximately $12,349,000. Worth Venture Partners LLC acquired a new stake in Alimera Sciences in the third quarter valued at approximately $1,840,000. Fifth Lane Capital LP purchased a new position in Alimera Sciences in the first quarter worth approximately $83,000. Finally, Vanguard Group Inc. raised its holdings in shares of Alimera Sciences by 61.1% in the 1st quarter. Vanguard Group Inc. now owns 1,045,460 shares of the biopharmaceutical company's stock valued at $4,077,000 after purchasing an additional 396,506 shares in the last quarter. Hedge funds and other institutional investors own 99.83% of the company's stock.

About Alimera Sciences

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).